First Time Loading...
M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 18.78 PLN 13.96% Market Closed
Updated: May 13, 2024

Intrinsic Value

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. [ Read More ]

The intrinsic value of one MAB stock under the Base Case scenario is 12.65 PLN. Compared to the current market price of 18.78 PLN, Mabion SA is Overvalued by 33%.

Key Points:
MAB Intrinsic Value
Base Case
12.65 PLN
Overvaluation 33%
Intrinsic Value
Price
M
Base Case Scenario

Valuation Backtest
Mabion SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MAB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Mabion SA

Provide an overview of the primary business activities
of Mabion SA.

What unique competitive advantages
does Mabion SA hold over its rivals?

What risks and challenges
does Mabion SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mabion SA.

Provide P/S
for Mabion SA.

Provide P/E
for Mabion SA.

Provide P/OCF
for Mabion SA.

Provide P/FCFE
for Mabion SA.

Provide P/B
for Mabion SA.

Provide EV/S
for Mabion SA.

Provide EV/GP
for Mabion SA.

Provide EV/EBITDA
for Mabion SA.

Provide EV/EBIT
for Mabion SA.

Provide EV/OCF
for Mabion SA.

Provide EV/FCFF
for Mabion SA.

Provide EV/IC
for Mabion SA.

Show me price targets
for Mabion SA made by professional analysts.

What are the Revenue projections
for Mabion SA?

How accurate were the past Revenue estimates
for Mabion SA?

What are the Net Income projections
for Mabion SA?

How accurate were the past Net Income estimates
for Mabion SA?

What are the EPS projections
for Mabion SA?

How accurate were the past EPS estimates
for Mabion SA?

What are the EBIT projections
for Mabion SA?

How accurate were the past EBIT estimates
for Mabion SA?

Compare the revenue forecasts
for Mabion SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mabion SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mabion SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mabion SA compared to its peers.

Compare the P/E ratios
of Mabion SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Mabion SA with its peers.

Analyze the financial leverage
of Mabion SA compared to its main competitors.

Show all profitability ratios
for Mabion SA.

Provide ROE
for Mabion SA.

Provide ROA
for Mabion SA.

Provide ROIC
for Mabion SA.

Provide ROCE
for Mabion SA.

Provide Gross Margin
for Mabion SA.

Provide Operating Margin
for Mabion SA.

Provide Net Margin
for Mabion SA.

Provide FCF Margin
for Mabion SA.

Show all solvency ratios
for Mabion SA.

Provide D/E Ratio
for Mabion SA.

Provide D/A Ratio
for Mabion SA.

Provide Interest Coverage Ratio
for Mabion SA.

Provide Altman Z-Score Ratio
for Mabion SA.

Provide Quick Ratio
for Mabion SA.

Provide Current Ratio
for Mabion SA.

Provide Cash Ratio
for Mabion SA.

What is the historical Revenue growth
over the last 5 years for Mabion SA?

What is the historical Net Income growth
over the last 5 years for Mabion SA?

What is the current Free Cash Flow
of Mabion SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mabion SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mabion SA

Current Assets 90.5m
Cash & Short-Term Investments 47.8m
Receivables 31.7m
Other Current Assets 11m
Non-Current Assets 117.8m
PP&E 112.4m
Intangibles 493k
Other Non-Current Assets 5m
Current Liabilities 55.3m
Accounts Payable 7.9m
Accrued Liabilities 3.2m
Other Current Liabilities 44.2m
Non-Current Liabilities 35.2m
Long-Term Debt 2.9m
Other Non-Current Liabilities 32.2m
Efficiency

Earnings Waterfall
Mabion SA

Revenue
151.7m PLN
Cost of Revenue
-37.1m PLN
Gross Profit
114.6m PLN
Operating Expenses
-47m PLN
Operating Income
67.6m PLN
Other Expenses
-26.3m PLN
Net Income
41.3m PLN

Free Cash Flow Analysis
Mabion SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MAB Profitability Score
Profitability Due Diligence

Mabion SA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
Exceptional ROIC
51/100
Profitability
Score

Mabion SA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

MAB Solvency Score
Solvency Due Diligence

Mabion SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Negative Net Debt
Low D/E
Long-Term Solvency
81/100
Solvency
Score

Mabion SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MAB Price Targets Summary
Mabion SA

Wall Street analysts forecast MAB stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAB is 16.07 PLN with a low forecast of 13.13 PLN and a high forecast of 19.43 PLN.

Lowest
Price Target
13.13 PLN
30% Downside
Average
Price Target
16.07 PLN
14% Downside
Highest
Price Target
19.43 PLN
3% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MAB Price
Mabion SA

1M 1M
+17%
6M 6M
+8%
1Y 1Y
+4%
3Y 3Y
-61%
5Y 5Y
-74%
10Y 10Y
-57%
Annual Price Range
18.78
52w Low
15.9
52w High
22.6
Price Metrics
Average Annual Return 13.68%
Standard Deviation of Annual Returns 117.52%
Max Drawdown -86%
Shares Statistics
Market Capitalization 303.5m PLN
Shares Outstanding 16 162 326
Percentage of Shares Shorted
N/A

MAB Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Mabion SA

Country

Poland

Industry

Biotechnology

Market Cap

303.5m PLN

Dividend Yield

0%

Description

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Contact

WOJ. LODZKIE
Konstantynow Lodzki
Kompleks Naukowo-Przemyslowy Biotechnologii Medycznej, ul. gen. Mariana Langiewicza 60
+48422077890.0
https://www.mabion.eu/

IPO

2010-08-10

Employees

213

Officers

CEO & President of Management Board
Mr. Krzysztof Kaczmarczyk
CFO & Member of Management Board
Mr. Grzegorz Grabowicz
Chief Operating & Scientific Officer and Member of the Management Board
Dr. Slawomir Jaros EMBA, Eng., Ph.D.
Chief Sales Officer & Member of Management Board
Mr. Adam Pietruszkiewicz
Chief Accountant
Aneta Turek

See Also

Discover More
What is the Intrinsic Value of one MAB stock?

The intrinsic value of one MAB stock under the Base Case scenario is 12.65 PLN.

Is MAB stock undervalued or overvalued?

Compared to the current market price of 18.78 PLN, Mabion SA is Overvalued by 33%.